Institutional Ownership Xtl Biopharmaceuticals LTD (XTLB)
This table provides information about the institutional ownership of Xtl Biopharmaceuticals LTD (XTLB). We have compiled data on the 6 institutions that hold shares in the stock, with a total of 453,499 shares, which have been reported (via 13F filing form) to have a value of $625,000.
| Holding | Report Date | shares Held | Holding Value (Reported) | Last Trade | Trade History |
|---|---|---|---|---|---|
|
Noked Capital LTD
Tel Aviv, L3 |
Nov 14, 2022 Q3 2022 |
198,888
shares
|
$274,465
0.02% of portfolio
|
Q3 2019
Reduced -0.0%
|
|
|
Noked Israel LTD
Ramat Hasharon, L3 |
Aug 14, 2025 Q2 2025 |
198,888
shares
|
$274,465
0.04% of portfolio
|
Q3 2019
Reduced -0.0%
|
|
|
Ken Griffin
Citadel Advisors LLC | Chicago, Il
|
May 15, 2025 Q1 2025 |
25,211
shares
|
$34,791
0.0% of portfolio
|
Q1 2025
New holding
|
|
|
Rhumbline Advisers
Boston, MA |
Aug 12, 2025 Q2 2025 |
17,261
shares
|
$23,820
0.0% of portfolio
|
Q2 2025
Added 57.58%
|
|
|
Morgan Stanley
New York, NY |
May 15, 2025 Q1 2025 |
13,251
shares
|
$18,286
0.0% of portfolio
|
Q1 2025
Reduced 27.79%
|
|
|
Ubs Group Ag
|
Aug 14, 2025 Q2 2025 |
1,336
shares
|
$1,843
0.0% of portfolio
|
Q2 2025
New holding
|
|
|
Concourse Financial Group Securities, Inc.
Birmingham, AL |
Aug 12, 2025 Q2 2025 |
0
shares
|
$0
100.0% of portfolio
|
Q2 2025
New holding
|